MAURELLI, MARTINA
 Distribuzione geografica
Continente #
NA - Nord America 846
EU - Europa 702
AS - Asia 215
OC - Oceania 7
SA - Sud America 2
Totale 1.772
Nazione #
US - Stati Uniti d'America 839
CN - Cina 168
IE - Irlanda 141
IT - Italia 132
GB - Regno Unito 115
SE - Svezia 108
FR - Francia 96
DE - Germania 56
FI - Finlandia 19
UA - Ucraina 13
IN - India 11
AU - Australia 7
IR - Iran 7
NL - Olanda 7
BE - Belgio 6
JP - Giappone 5
TR - Turchia 5
MX - Messico 4
SG - Singapore 4
CA - Canada 3
ID - Indonesia 3
VN - Vietnam 3
ES - Italia 2
HK - Hong Kong 2
KR - Corea 2
LK - Sri Lanka 2
RO - Romania 2
TH - Thailandia 2
BR - Brasile 1
CL - Cile 1
HR - Croazia 1
IL - Israele 1
LU - Lussemburgo 1
PL - Polonia 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.772
Città #
Chandler 244
Dublin 129
Ashburn 100
Southend 87
Beijing 54
Jacksonville 42
Lawrence 34
Princeton 34
New York 28
Wilmington 28
Verona 24
Sindelfingen 20
Woodbridge 19
Washington 18
Monza 16
Helsinki 14
Jinan 14
Seattle 12
Bethnal Green 11
Ann Arbor 10
Houston 10
Milan 10
Bologna 9
Dongguan 8
Nanjing 8
Redwood City 8
Chieri 7
Fairfield 7
Frankfurt am Main 6
Rome 6
Bari 5
Brindisi 5
Redmond 5
Shenyang 5
Brussels 4
Changsha 4
Ghaziabad 4
Hebei 4
Jiaxing 4
Konya 4
Nanchang 4
Amsterdam 3
Canberra 3
Dearborn 3
Esslingen am Neckar 3
Fuzhou 3
Guangzhou 3
Hangzhou 3
Kolkata 3
Ningbo 3
Norwalk 3
Oakland 3
Oullins 3
Povegliano Veronese 3
Shahr-e Kord 3
Shanghai 3
Tianjin 3
Zhengzhou 3
Atlanta 2
Bangkok 2
Baoding 2
Barcelona 2
Binasco 2
Brisbane 2
Busto Arsizio 2
Cambridge 2
Chicago 2
Colombo 2
Falconara Marittima 2
Florence 2
Gangbuk-gu 2
Glasgow 2
Guadalajara 2
Haikou 2
Hanover 2
Isorella 2
Jumet 2
Latiano 2
Le Mans 2
Leawood 2
Legnago 2
Lugo 2
Malang 2
Marana 2
Menlo Park 2
Monterrey 2
New Delhi 2
Phoenix 2
Singapore 2
Taiyuan 2
Taizhou 2
Tappahannock 2
Toronto 2
Tower Hamlets 2
Tsukuba 2
Urbino 2
Woolwich 2
Andover 1
Bacau 1
Belgrade 1
Totale 1.197
Nome #
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 95
null 80
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 75
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 59
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 54
Amicrobial Pustulosis of the Folds: Report of Three New Cases 54
A systematic review of treatments for pityriasis lichenoides 51
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 50
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 50
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 49
Idiopathic lichenoid and granulomatous dermatitis 49
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 47
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 46
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 46
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 45
Interferon-beta injection site reactions in patients with multiple sclerosis. 44
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 42
Adrenergic urticaria successfully treated with omalizumab 42
Annular Erythema: New and Revisited Variants 40
Biological agents targeting interleukin-13 for atopic dermatitis 40
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 39
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 39
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 38
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 37
Clinical profile and co-infections of urethritis in males 36
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 36
A case of genital primary syphilis with superimposed impetigo 35
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 35
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 33
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 30
Eosinophilic annular erythema successfully treated with cyclosporine 28
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 27
Uncommon Non‑Infectious Annular Dermatoses 26
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 26
A man with a widespread bullous eruption 25
Visual Vignette 24
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 23
Targeting IL-4 for the Treatment of Atopic Dermatitis 23
Pruritus as a Distinctive Feature of Type 2 Inflammation 22
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 20
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 18
Lymphoplasmacytic plaque effectively treated with imiquimod 18
Advanced Glycation End Products and Psoriasis 16
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 16
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 15
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 14
Atopic Dermatitis in the Elderly Population 13
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 13
Tailored biological treatment for patients with moderate-to-severe psoriasis 13
The Combination of Dupilumab with Other Monoclonal Antibodies 11
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 9
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 7
Price variability of TNF-α inhibitor biosimilars among European countries 7
Overview of Atopic Dermatitis in Different Ethnic Groups 6
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 3
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 2
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 2
Totale 1.843
Categoria #
all - tutte 8.995
article - articoli 8.819
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 176
Totale 17.990


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 4 1 0
2019/202092 7 2 1 0 21 10 2 2 5 13 16 13
2020/2021127 13 13 3 21 19 16 10 1 6 2 13 10
2021/2022228 13 26 0 18 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024521 16 30 56 51 52 126 115 42 8 25 0 0
Totale 1.843